Neuroblastoma (NB), a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. In addition to genetic abnormalities, recent studies have indicated that epigenetic aberrations also contribute toward NB pathogenesis. However, the epigenetic mechanisms underlying the pathogenesis of NB are largely unknown. Inhibition of euchromatic histone-lysine N-methyltransferase 2 (EHMT2) was evaluated through the measurement of H3K9Me2 levels. Cell proliferation was examined by cell counting in human NB cell lines (LA1-55n, IMR-5, and NMB). The RNA expression of EHMT2, MYCN, and p21 was measured by real-time PCR. The expression of PCNA, MYCN, p53, cyclinD1, H3, H3K27M2, and H3K9Me2 was examined by western blot analysis. In-vitro invasion and the effects of the EHMT2 inhibitor (BIX-01294) were assessed in the Transwell chamber assay. Caspase 3 and 8 activities were measured using a Caspase-Glo assay kit. The level of overall DNA methylation was measured by liquid chromatography-mass spectroscopy. BIX-01294, a specific inhibitor of EHMT2 (a key enzyme for histone H3 dimethylation at lysine-9), specifically decreases the overall H3K9Me2 level but not H3K27Me2. The inhibition of EHMT2 decreased the proliferation of NB cells and induced apoptosis by increasing caspase 8/caspase 3 activity. BIX-01294 inhibited NB cell mobility and invasion. This was accompanied by a decreased expression of the MYCN oncogene. Inhibition of EHMT2 enhanced a doxorubicin-induced inhibitory effect on cell proliferation. Finally, EHMT2 inhibition modulated overall DNA methylation levels in NB cells. Our results show that histone-lysine methylation is involved in cell proliferation, apoptosis, cell invasion, and overall DNA methylation in human NB cells. Further understanding of this mechanism may provide an insight into the pathogenesis of NB progression and lead to novel treatment strategies.
Introduction
Neuroblastoma (NB) is the most common extracranial pediatric solid tumor and is characterized by a broad spectrum of clinical behavior [1, 2] . Although some patients have high cure rates, B45% of the patients present with a widely disseminated and high-risk disease that remains difficult to cure. NB originates from the neural crest precursor cells as a result of genetic and epigenetic alterations that disrupt the normal developmental program. It has been reported that a CpG island methylator phenotype (CIMP) is a powerful prognostic factor, independent of age and stage in NB [3, 4] . Our group and others have shown that a poor outcome is associated with the hypermethylation of a number of tumor suppressor genes including RASSF1A, CASP8, and HIN-1 [5] [6] [7] . In preclinical studies, we found that NB tumor growth was impaired with agents that inhibit DNA methyltransferase and histone deacetylase, indicating the important role that the epigenome plays in NB tumor growth [8] [9] [10] .
Histone-lysine methyltransferase EHMT2 is a key enzyme for histone H3 dimethylation at lysine-9 (H3K9me2), which is an epigenetic mark of gene suppression [11] [12] [13] . EHMT2 is highly expressed in human cancer cells and plays a key role in promoting cancer invasion and metastasis. The RNAi-mediated knockdown of EHMT2 in highly invasive lung cancer cells inhibited cell migration and invasion in vitro as well as metastasis in vivo [14] . The suppression of EHMT2 by knockdown inhibited cell growth in prostate cancer cells and led to morphologically senescent cells with telomere abnormalities [15] . These studies indicated that EHMT2 is likely required for the maintenance of the malignant phenotype. However, the involvement of EHMT2 in the regulation of the NB phenotype and cell proliferation remains unknown. In this study, we investigated the effect of the inhibition of EHMT2 on NB proliferation and apoptosis. We also determined the effect of EHMT2 inhibition on cell invasion and overall DNA methylation in NB cells.
The cell number was determined using a hemocytometer. Trypan blue staining was used to differentiate between dead and live cells. LA1-55n, IMR-5, and NMB cells were plated in six-well plates and cultured overnight. BIX-01294 was added and cells were incubated for 24 and 48 h at the indicated concentrations.
Flow cytometry for analysis of cell cycle LA1-55n cells were harvested at the completion of the respective BIX-01294 treatments. The cells were washed with a PBS (pH 7.4) twice and then subsequently fixed with 70% ethyl alcohol for 15 min on ice. The cells were then centrifuged at 2000 rpm to obtain pellets and the residual alcohol was aspirated. Cells were then digested with DNase-free RNase A (2 mg/ml) for 30 min at 371C. Before flow cytometric analysis, cells were resuspended in 1 ml of 10 mg/ml propidium iodide (Sigma-Aldrich) for staining cellular DNA as described previously [15] . Cellular DNA content was then analyzed using an Epics XL-MCL Flow Cytometer (Beckman Coulter, Fullerton, California, USA).
Cell invasion assay
The in-vitro invasive properties of LA1-55n cells were evaluated using BD Matrigel Biocoat invasion chambers (BD Biosciences, Bedford, Massachusetts, USA). Briefly, after transwells and inserts were warmed, 1 Â 10 5 /ml LA1-55n cells in 0.5 ml of media with 1% FBS were added to the upper surface of the filter for each assay and 0.75 ml of media with 10% FBS were used in the well as a chemoattractant. After 2 days, noninvaded cells in the upper chamber were removed with cotton swabs and invaded cells were fixed with 100% methanol for 2 min and then stained with 1% toluidine blue in a 1% borax solution for 2 min. For each insert, at least five random microscopic fields (Â 200 magnification) were counted. Experiments were conducted in triplicate. The percentage of invasion was calculated by the number of cells invading through the Matrigel membrane divided by the number of cells that migrated through the control membrane.
cDNA synthesis and SYBR green real-time PCR RNA was isolated from untreated and BIX-01294-treated LA1-55n cells using Trizol reagent (Invitrogen). Reverse transcription was performed using Superscript III (Invitrogen) according to the manufacturer's instructions. SYBR green real-time PCR reactions were set up containing 1X Power SYBR Green Master Mix (Applied Biosystems, Foster City, California, USA), and 250 nmol/l forward and reverse primers in a 20 ml reaction. All assays were carried out in a 96-well format. Real-time fluorescence detection of PCR products was carried out using a StepOne Plus Real-Time PCR System (Applied Biosystems) under the following thermocycling conditions: one cycle of 951C for 10 min; 40 cycles of 951C for 30 s; and 601C for 1 min. The primer sequences for EHMT2 are sense: GCTCCGACGTG TGGTTTGC; antisense: CGATTTCCCACCCCAAGTC. The other primer sequences are as described previously [18] . The sequences of the primers for real-time PCR were designed using the Primer Express software (Applied Biosystems). b-Actin was used as an endogenous control for gene expression. For data analysis, the comparative method (DD C t ) was used to calculate the relative quantities of a nucleic acid sequence.
Western blot analysis
Total proteins from LA1-55n cells were extracted by lysing the cells in cell lysis buffer (RIPA buffer: 20 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l EGTA, 1% IGEPAL, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l b-glycerophosphate) containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich). Protein concentrations were determined using the Bradford protein assay kit (Bio-Rad, Hercules, California, USA). Equal amounts of total protein (10-25 mg) from cells were subjected to SDS-polyacrylamide gel electrophoresis. Proteins were then transferred to a nitrocellulose membrane for 90 min at 100 V. Membranes were blocked for 1 h at room temperature in a Tris-buffered saline (TBS) containing 5% nonfat powdered milk. The membranes were then probed with a primary antibody in TBS with 2.5% nonfat powdered milk at concentrations from 1 : 500 to 1 : 20 000 dilutions and preincubated for overnight according to the manufacturer's instructions for each antibody. In all cases, a secondary antibody labeled with horseradish peroxidase (GE Healthcare, Piscataway, New Jersey, USA) was used at concentrations from 1 : 2000 to 1 : 20 000 for 1 h at room temperature, and immunoreactive bands were detected using SuperSignal West Pico Chemi-luminescent Substrate (Pierce, Rockford, Illinois, USA) and recorded on a photosensitive film. The primary antibodies used for this study include anti-cyclinD1 (Sigma-Aldrich), anti-PCNA (Proteintech, Chicago, Illinois, USA), anti-p53 (Santa Cruz, Santa Cruz, California, USA), anti-MycN (Santa Cruz), anti-H3K9me2, H3K27Me2 (Abcam, Cambridge, Massachusetts, USA), H3 (Abcam), and anti-b-actin (Santa Cruz).
Caspase assays
Caspase 3 and 8 activities in LA1-55n cells were measured using the Caspase-Glo assay kit (Promega, Madison, Wisconsin, USA). Briefly, the cells were plated in white-walled 96-well plates (Corning Incorporated, Lowell, Massachusetts, USA), and incubated for 24 h. For caspase inhibition assay, caspase 8 inhibitor II, and negative control were added 30 min before adding BIX-01294. BIX-01294 was added to the medium and incubated for 24 h. The proluminescent substrate containing DEVD or LETD (EMD Millipore), which are cleaved by caspase 3 or caspase 8, respectively, was added to each well and incubated at room temperature for 1 h. The luminescence of each sample was measured in a plate-reading luminometer as directed by the luminometer manufacturer (Promega).
Liquid chromatography/mass spectroscopy
Analysis of total cytosine methylation was carried out by liquid chromatography/mass spectroscopy (LC/MS) as described previously [19] . Briefly, genomic DNA from BIX-01294-treated and untreated LA1-55n cells was hydrolyzed to nucleosides by adding 5 U nuclease P1 (Sigma-Aldrich) at 371C for 2 h, 0.002 U of venom phosphodiesterase I (Sigma-Aldrich) at 371C for 2 h, and 0.5 U of alkaline phosphatase at 371C for 1 h. Stock solutions of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine were prepared in water. An eight-point stock mixture of a standard was carefully prepared to yield an exact known concentration ratio of 2 0 -deoxycytidine to 5-methyl-2 0 -deoxycytidine. The concentration of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine in each sample was calculated from the standard curve. Each DNA sample was analyzed in triplicate. 25 ml (80 ng) of sample was injected into the LC and run through an Atlantis DC18 silica column (Waters Corporation, Milford, Massachusetts, USA), and identification of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine was carried out by mass spectra of chromatographic peaks.
Statistical analyses
Statistical analyses were carried out using a two-tailed Student's t-test. A P value less than 0.05 was considered statistically significant.
Results

Effect of EHMT2 inhibition on LA1-55n cell proliferation
To test whether EHMT2 regulates NB cell proliferation, LA1-55n, IMR-5, and NMB NB cells were cultured for 24 and 48 h in media containing various concentrations of BIX-01294, the specific EHMT2 inhibitor. Trypan blue exclusion analysis showed that EHMT2 inhibition suppressed LA1-55n cell proliferation in a dose-dependent and time-dependent manner. For 24-h treatment, at concentrations ranging from 2.5 to 10 mg/ml, BIX-01294 significantly inhibited LA1-55n, IMR-5, and NMB NB cell proliferation as shown in Fig. 1a -c (P < 0.01). BIX-01294 treatment resulted in decreased cell numbers of NMB cells even at the concentration of 1 mg/ml. However, there was no significant change in cell number for LA1-55n and IMR-5 after treatment with BIX-01294 at a concentration of 1 mg/ml, indicating that NMB cells were much more sensitive in response to BIX-01294 treatment.
For 48-h treatment ( Fig. 1d-f ), three NB cells showed the inhibitory effect of BIX-01294 on cell proliferation at concentrations ranging from 1 to 10 mg/ml. Moreover, BIX-01294 treatment resulted in decreased cell number of NMB cells at the concentration of 0.5 mg/ml. However, there was no significant change of cell number for LA1-55n and IMR-5 after treatment with BIX-01294 at the concentration of 0.5 mg/ml.
Effect of EHMT2 inhibition on the H3K9Me2 level in LA1-55n cells
To determine whether BIX-01294 induced the inhibitory effect of NB cell proliferation through EHMT2, western blot analysis was carried out in LA1-55n cells using antibody against H3K9Me2, as EHMT2 is a key enzyme for histone H3 dimethylation at lysine-9 (H3K9me2). As shown in Fig. 2a and b, the overall level of H3K9Me2 was decreased in LA1-55n cells treated with EHMT2 inhibitor (BIX-01294) compared with the control. However, the overall level of H3K27Me2 was not altered in LA1-55n cells treated with BIX-01294 as shown in Fig. 2a and c, suggesting that BIX-01294 specifically targets EHMT2, leading to a decreased level of H3K9Me2. To test whether the decreased level of H3K9me2 was because of an altered level of EHMT2 expression, realtime PCR was performed. As shown in Fig. 2d , the expression of EHMT2 was not significantly decreased in BIX-01295-treated LA1-55n compared with the control, indicating that BIX-01294-induced decreased level of H3K9Me2 is through inhibition of EHMT2 activity.
Effect of EHMT2 inhibition on LA1-55n cell cycle progression
To determine whether inhibition of LA1-55n cell proliferation is because of an increase in cell cycle arrest, LA1-55n cells were plated and cultured for 24h in media containing 10% FBS, and cells were treated with BIX-01294 or vehicle for 24 h. Cells were stained with propidium iodide to study the cell cycle progression. As shown in Fig. 3a , EHMT2 inhibition showed no significant change in cell cycle progression.
To determine whether EHMT2 inhibition altered the expression of cell proliferation-related genes, protein expression of p53, Cyclin D1, and PCNA genes was analyzed by western blot. As shown in Fig. 3b , there was no marked difference in the expression of CCND1, p53, or PCNA between the control and BIX-01294-treated NB cells. In addition, p21 RNA expression was not induced in LA1-55n cells treated with BIX-01294 ( Fig. 3c ).
Effect of EHMT2 inhibition on motility and invasive abilities of LA1-55n cells
To determine whether EHMT2 inhibition affects motility and invasion of LA1-55n cells, a transwell chamber assay was performed. As shown in Fig. 4a , both the number of migrating and invading LA1-55n cells were lower in BIX-01294-treated cells than those in the nontreated cells (17±2.1 vs. 12±2.01, P < 0.01; 9±1.8 vs. 3.8±1.2, P < 0.01). Moreover, the index of invading cells was lower in BIX-01294-treated groups compared with control groups (53 vs. 32%, P < 0.01). The data suggested that inhibition of EHMT2 significantly suppressed the motility and invasive ability of LA1-55n cells. To determine the correlation between the expression of MYCN and the invasive ability of NB cells, MYCN expression was examined by real-time PCR in LA1-55n cells treated with BIX-01294. As shown in Fig. 4b and c, the expression of MYCN was significantly decreased in BIX-01294-treated cells compared with the control by 50% (24 h treatment) and 40% (48 h treatment), respectively (P < 0.01). To determine whether the protein level of MYCN was also decreased in response to BIX-01294 treatment, western blot analysis was carried out in LA1-55n cells treated with vehicle and BIX-10294. As shown in Fig. 4d , EHMT2 inhibition resulted in a decreased MYCN protein level in a dose-dependent manner.
Effect of EHMT2 inhibition on caspase activity and doxorubicin-induced inhibitory effect of cell proliferation
To determine whether EHMT2 inhibition attenuated cell proliferation through the apoptotic pathway, caspase 3/7 and 8 activities were measured. As shown in Fig. 5a , caspase 3/7 were activated after treatment with BIX-01294 in a dose-dependent manner. At a concentration of 2.5 mg/ml, BIX-01294 activated caspase 3/7 activity by 130% (P < 0.01); at a concentration of 10 mg/ml, BIX-01294 activated caspase 3/7 activity by 220% (P < 0.01). As a positive control, staurosporine at a concentration of 1 mmol/l activated caspase 3/7 activity by 280% compared with untreated cells (P < 0.01). Activated caspase 8 was also observed in LA1-55n cells treated with BIX-01294. At concentrations ranging from 2.5 to 10 mg/ml, BIX-01294 activated caspase 8 activity by 130-150% (P < 0.01) as shown in Fig. 5b . To determine whether EHMT2 inhibition enhanced a doxorubicin-induced inhibitory effect on cell proliferation, we initially determined the dose effect of doxorubicin on cell proliferation. As shown in Fig. 5c , at concentrations above 12 ng/ml, doxorubicin induced a marked decrease in cell number, indicating that doxorubicin inhibited cell proliferation in a dose-dependent manner. To further determine the effect of EHMT2 inhibition on cell death, 40 mmol/l of LETD caspase 8 inhibitor was added to the media 30 min before BIX-01294 treatment and cells were incubated in10 mmol/l of BIX-01294 for 24 h. The dead cells were counted by trypan blue exclusion. As shown in Fig. 5d , EHMT2 inhibition significantly increases cell death. However, inhibition of caspase 8 activity by LETD attenuated BIX-01294-induced inhibitory effect of cell proliferation. Next, we determined whether EHMT2 inhibition enhanced the doxorubicin-induced inhibitory effect on cell proliferation. As shown in Fig. 5e , BIX-01294 treatment at a concentration of 5 mg/ml in combination with doxorubicin (12 ng/ml) markedly increased cell death as compared with either single treatment.
Effect of EHMT2 inhibition on overall DNA methylation
As a histone modifier, BIX-01294 modulated histone modification by inhibiting EHMT2 activity. To determine whether the interplay between histone modification and DNA methylation occurred, LC/MS analysis was carried out to determine the percentage of cytosine methylation in vehicle-treated and BIX-01294-treated LA1-55n cells. Using a standard curve average of 5-methylcytosine, the level of 5-methylcytosine increased significantly (P < 0.01) as compared with controls by 1.7-and 1.9-fold following 24 and 48 h of BIX-01294 treatment ( Fig. 6a and b ), suggesting that EHMT2 inhibition affected the pattern of DNA methylation in LA1-55n NB cells.
Discussion
There are several lines of evidence indicating that the level of EHMT2 expression is associated with a malignant phenotype in a variety of cancer types [12, 14, 20] . Highly expressed EHMT2 has been reported in metastatic prostate cancer, lymphomas, and aggressive breast cancer [21] . In lung cancer, EHMT2 represents a metastasis promoter by silencing the cell adhesion molecular Ep-CAM [14] . Although the role of EHMT2 in NB progression has not been characterized, another wellknown histone marker, trimethylation of histone 3 on lysine 27 (H3K27Me3), associated with gene silencing, was studied recently [22] . H3K27Me3 is mediated by the lysine methyltransferase EZH2, which is the enzymatically active component of the polycomb repressor complex 2 (PRCR2) [21, 23] . RNAi-mediated knockdown of EZH2 or pharmacological inhibition of EZH2 inhibited cell growth and induced neurite extension with an increase in the expression of tumor suppressors CLU, NGFR, and RUNX3, suggesting that EZH2 plays an essential role in the maintenance of an undifferentiated phenotype in NB tumors [22] . We postulated that EHMT2 may also play an important role in the growth regulation of NB cells. In this study, BIX-01294 induced an inhibitory effect on cell proliferation. At 2.5 mg/ml of BIX-01294, there was no marked cell arrest by flow cytometry. Because it has been reported that EHMT2 is involved in p21 promoter activity [11] , we determined the expression level of p21 in BIX-01294-treated LA1-55n cells vs. vehicle-treated cells. No marked induction of p21 expression was observed. In addition, the expression of cell proliferation-related proteins of CCND1, p53, and PCNA was not altered between vehicle-treated and BIX-01294-treated NB cells, suggesting that the EHMT2-mediated inhibitory effect of gene expression such as p21 is cell type specific.
Next, we evaluated the role of EHMT2 in cellular apoptosis. We found that the induction of apoptosis in NB cells played a role in the regulation of cell proliferation. Caspase 3 and 8 activities were significantly increased within 24 h after treatment with the EHMT2 inhibitor. Studies using caspase 8-specific inhibitors further have reported the role of EHMT2 in the regulation of cell growth through apoptotic pathways. Our studies are consistent with a previous report showing that knockdown of EHMT2 by siRNA resulted in the suppression of growth of cancer cells and possibly caused apoptotic cell death in bladder and lung cancer cells [20] .
Doxorubicin is a well-known apoptotic inducer in NB [24] [25] [26] . Doxorubicin-induced apoptosis in caspase 8-deficient neuroblastoma cells (SK-N-SH) is mediated through direct action on mitochondria [25] . In this study, we found that BIX-01294 enhanced the doxorubicininduced inhibitory effect on cell proliferation in LA1-55n cells. We have reported previously that methylation of the caspase 8 promoter is higher in N-type tumorigenic LA1-55n cells than in S-type non-tumorigenic LA1-5s NB cells. The level of caspase 8 expression was upregulated in LA1-55n cells treated with 5-Aza-dC, a DNA methyltransferase inhibitor, suggesting that the expression of caspase 8 is regulated by DNA methylation [18] . Although the expression of caspase 8 is relatively lower in LA1-55n cells because of its promoter methylation, the basal level of caspase 8 was sufficiently activated by BIX-01294 treatment, which was confirmed by enhanced activation of caspase 8. Moreover, the BIX-01294-induced cell death was attenuated by a caspase 8 inhibitor.
Although EHMT2 plays an essential role in histone modification leading to dysregulation of epigenetic pathways in cancer progression, little is known about how DNA methylation is mediated by EHMT2. In murine embryonic stem cells, EHMT2 is required for de-novo DNA methylation and establishment of proviral silencing [27] .
In this study, we showed that EHMT2 inhibition resulted in the modulation of overall DNA methylation as analyzed by LC/MS. Inhibition of EHMT2 is capable of altering the distribution of DNA methylation, which is associated with changes in the NB phenotype, including downregulation of MYCN expression and a decrease in cell-invasive ability. Our studies indicated that a small compound, BIX-01294, which specifically inhibits EHMT2 enzymatic activity, is not only able to modulate histone modification by reducing H3K9Me2 levels as described previously [28, 29] but also alters genomewide DNA methylation. Interestingly, DNA hypermethylation profiles are associated with glioma subtypes and EZH2 mRNA expression [30] . To our knowledge, this is the first report to show that EHMT2 inhibition mediates changes in malignant phenotype and overall DNA methylation in NB. This is also consistent with our previous studies showing that an interplay between histone methylation and DNA methylation occurred [18] , and DNA methylation and histone modifications act in concert to form an appropriate epigenome leading to modulation of cancer phenotype [31] . Although the molecular mechanisms underlying enhanced overall DNA level regulated by BIX-01294 is unknown, there are some evidences showing that besides DNA methyltransferase, some other proteins including Tet 1, 2, and 3, AID, and APOBEC1 are also involved in the modulation Effect of EHMT2 inhibition on the overall DNA methylation level. Stock solutions of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine were prepared in water. An eight-point stock mixture of a standard was carefully prepared to yield an exact known concentration ratio of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine. DNA methylation was determined by liquid chromatography/mass spectroscopy. Genomic DNA was isolated from control and LA1-55n cells treated with 5 mg/ml BIX-01294 for 24 h (a) or 48 h (b), respectively. DNA was then subjected to digestion with nuclease P1, venom phosphodiesterase I, and alkaline phosphatase, respectively. The concentration of 2 0 -deoxycytidine and 5-methyl-2 0 -deoxycytidine in each sample was calculated from the standard curve. Each DNA sample was analyzed in triplicate. *Statistically significant difference (P < 0.01) between the vehicle-treated and BIX-01294-treated cells.
of overall DNA methylation levels related to epigenetic reprogramming [32] [33] [34] [35] . The extent of both DNA hypomethylation and hypermethylation in NB cells is likely to reflect distinctive biological and clinical characteristics, and understanding of the epigenetic reprogramming mechanisms that occur in NB should provide important new information about the relationship between the NB phenotype and epigenetic state.
Taken together, our results indicate that the inhibition of EHMT2 is capable of inhibiting NB proliferation by enhancing caspase activities, leading to apoptosis of NB cells. In addition, inhibition of EHMT2 modulated the phenotype and overall DNA methylation in NB cells.
Understanding the role of the interaction between histone modification and DNA methylation and how they function at the molecular level may shed light on the mechanisms involved in the development and progression of NB.
